* Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected
to show a
rise in quarterly revenue when it reports results on August
15.
* The New York City-based company is expected to report
revenue
of $620 thousand, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Lucid Diagnostics
Inc is
for a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lucid
Diagnostics
Inc is $3, above its last closing price of $1.47.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.34 -0.35 -0.40 Missed -14.7
Dec. 31 2023 -0.37 -0.38 -0.23 Beat 39.3
Sep. 30 2022 -0.42 -0.40 -0.39 Beat 1.7
Jun. 30 2022 -0.36 -0.36 -0.41 Missed -14.2
Mar. -0.35 -0.33 -0.35 Missed -5.3
31 2022
Dec. 31 2021 -0.20 -0.20 -0.32 Missed -58
Sep. 30 2021 -0.32 -0.32 -0.49 Missed -54.7
This summary was machine generated August 11 at 16:42 GMT. All
figures in US dollars unless otherwise stated